Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway

Hongjie Zhu, Mikhail B. Bogdanov, Stephen H. Boyle, Wayne Matson, Swati Sharma, Samantha Matson, Erik Churchill, Oliver Fiehn, John A. Rush, Ranga R. Krishnan, Eve Pickering, Marielle Delnomdedieu, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%], respectively, χ2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-MTPOL.

Original languageEnglish (US)
Article numbere68283
JournalPLoS One
Volume8
Issue number7
DOIs
StatePublished - Jul 17 2013

Fingerprint

Sertraline
Major Depressive Disorder
melatonin
Melatonin
placebos
Placebos
5-Methoxytryptamine
kynurenine
Kynurenine
serotonin
Serotonin
metabolomics
Metabolomics
Tryptophan
tryptophan
Therapeutics
pretreatment
electrochemistry
therapeutics
antidepressants

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Zhu, H., Bogdanov, M. B., Boyle, S. H., Matson, W., Sharma, S., Matson, S., ... Kaddurah-Daouk, R. (2013). Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway. PLoS One, 8(7), [e68283]. https://doi.org/10.1371/journal.pone.0068283

Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway. / Zhu, Hongjie; Bogdanov, Mikhail B.; Boyle, Stephen H.; Matson, Wayne; Sharma, Swati; Matson, Samantha; Churchill, Erik; Fiehn, Oliver; Rush, John A.; Krishnan, Ranga R.; Pickering, Eve; Delnomdedieu, Marielle; Kaddurah-Daouk, Rima.

In: PLoS One, Vol. 8, No. 7, e68283, 17.07.2013.

Research output: Contribution to journalArticle

Zhu, H, Bogdanov, MB, Boyle, SH, Matson, W, Sharma, S, Matson, S, Churchill, E, Fiehn, O, Rush, JA, Krishnan, RR, Pickering, E, Delnomdedieu, M & Kaddurah-Daouk, R 2013, 'Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway', PLoS One, vol. 8, no. 7, e68283. https://doi.org/10.1371/journal.pone.0068283
Zhu, Hongjie ; Bogdanov, Mikhail B. ; Boyle, Stephen H. ; Matson, Wayne ; Sharma, Swati ; Matson, Samantha ; Churchill, Erik ; Fiehn, Oliver ; Rush, John A. ; Krishnan, Ranga R. ; Pickering, Eve ; Delnomdedieu, Marielle ; Kaddurah-Daouk, Rima. / Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{1d10165dedd840c0999043b0790e188a,
title = "Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway",
abstract = "Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for placebo (21/35 [60{\%}] vs. 20/40 [50{\%}], respectively, χ2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-MTPOL.",
author = "Hongjie Zhu and Bogdanov, {Mikhail B.} and Boyle, {Stephen H.} and Wayne Matson and Swati Sharma and Samantha Matson and Erik Churchill and Oliver Fiehn and Rush, {John A.} and Krishnan, {Ranga R.} and Eve Pickering and Marielle Delnomdedieu and Rima Kaddurah-Daouk",
year = "2013",
month = "7",
day = "17",
doi = "10.1371/journal.pone.0068283",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway

AU - Zhu, Hongjie

AU - Bogdanov, Mikhail B.

AU - Boyle, Stephen H.

AU - Matson, Wayne

AU - Sharma, Swati

AU - Matson, Samantha

AU - Churchill, Erik

AU - Fiehn, Oliver

AU - Rush, John A.

AU - Krishnan, Ranga R.

AU - Pickering, Eve

AU - Delnomdedieu, Marielle

AU - Kaddurah-Daouk, Rima

PY - 2013/7/17

Y1 - 2013/7/17

N2 - Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%], respectively, χ2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-MTPOL.

AB - Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%], respectively, χ2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-MTPOL.

UR - http://www.scopus.com/inward/record.url?scp=84880405465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880405465&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0068283

DO - 10.1371/journal.pone.0068283

M3 - Article

C2 - 23874572

AN - SCOPUS:84880405465

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e68283

ER -